Generics and currency effects take their toll on Astellas
This article was originally published in Scrip
Executive Summary
Net sales at Astellas rose by just 1% to ¥974.9 billion ($10.48 billion) in the fiscal year to 31 March, held back by US generic competition for its top product and exchange rate effects.